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We	  used	  a	  murine	  model	  to	  assess	  in	  vivo	  the	  evolving	  biomechanical	  properties	  of	  
tissue	  engineered	  vascular	  grafts	  (TEVGs)	  implanted	  in	  the	  arterial	  circulation.	  	  The	  
initial	  polymeric	  tubular	  scaffold	  was	  fabricated	  from	  (poly)lactic	  acid	  (PLA)	  and	  
coated	  with	  a	  50:50	  copolymer	  of	  (poly)caprolactone	  and	  (poly)lactic	  acid	  
(P[PC/LA]).	  	  Following	  seeding	  with	  syngeneic	  bone	  marrow	  derived	  mononuclear	  
cells,	  the	  TEVGs	  (n=50)	  were	  implanted	  as	  aortic	  interposition	  grafts	  in	  wild-­‐type	  
mice	  and	  monitored	  serially	  using	  ultrasound.	  A	  custom	  biaxial	  mechanical	  testing	  
device	  was	  used	  to	  quantify	  in	  vitro	  the	  circumferential	  and	  axial	  mechanical	  
properties	  of	  grafts	  explanted	  at	  3	  or	  7	  months.	  At	  both	  times,	  the	  TEVGs	  were	  
biaxially	  stiffer	  than	  native	  tissue.	  	  We	  treated	  the	  TEVGs	  with	  either	  elastase	  or	  
collagenase	  to	  delineate	  individual	  contributions	  of	  these	  structural	  proteins	  to	  the	  
overall	  properties.	  	  Elastin	  conferred	  an	  insignificant	  contribution	  whereas	  collagen	  
contributed	  significantly	  to	  TEVG	  stiffness.	  	  The	  mechanical	  properties	  were	  
compared	  with	  the	  underlying	  microstructure,	  which	  was	  inferred	  from	  traditional	  
histology	  and	  immunohistochemistry.	  	  Analysis	  revealed	  smooth	  muscle	  cell	  layers,	  
appropriate	  collagen	  deposition,	  and	  increasing	  elastin	  production.	  	  In	  addition,	  
significant	  amounts	  of	  residual	  scaffold	  were	  present	  at	  both	  3	  and	  7	  months,	  which	  
likely	  contributed	  to	  the	  high	  stiffness	  seen	  in	  mechanical	  testing.	  	  These	  results	  
suggest	  that	  PLA	  may	  have	  inadequate	  degradation	  in	  vivo,	  which	  impairs	  cell-­‐
mediated	  development	  of	  vascular	  neotissue	  having	  properties	  closer	  to	  native	  
arteries.	  	  Assessing	  contributions	  of	  individual	  components,	  such	  as	  elastin	  and	  
	  	  
	  
collagen,	  to	  the	  developing	  neovessel	  promises	  to	  guide	  computational	  modeling	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Clinical	  Problem-­‐	  Cardiovascular	  Disease:	  	  
Cardiovascular	  disease	  (CVD)	  is	  the	  number	  one	  killer	  in	  the	  United	  States,	  
accounting	  for	  1	  of	  every	  3	  deaths.1	  In	  the	  pediatric	  population,	  congenital	  heart	  
defects	  (CHD)	  are	  the	  most	  common	  congenital	  malformation	  in	  newborns,	  found	  in	  
1%	  of	  all	  live	  births.1	  Similarly,	  the	  prevalence	  of	  peripheral	  arterial	  disease	  (PAD)	  
in	  the	  United	  States	  is	  estimated	  to	  be	  4.3%,	  which	  corresponds	  to	  roughly	  5	  million	  
individuals.2	  	  
While	  CVD,	  CHD,	  and	  PAD	  represent	  diverse	  pathology	  and	  structural	  defects,	  
they	  are	  linked	  by	  resulting	  ischemia	  caused	  by	  obstruction	  or	  misdirection	  of	  blood	  
flow.	  	  In	  the	  adult	  population,	  ischemia	  in	  the	  coronary	  circulation	  can	  trigger	  
myocardial	  infarction	  (MI)	  whereas	  ischemia	  in	  the	  peripheral	  circulation	  can	  cause	  
claudication	  and	  contribute	  gangrenous	  necrosis.	  	  In	  the	  pediatric	  population,	  the	  
severity	  CHD	  affecting	  the	  heart	  and	  great	  vessels	  is	  based	  on	  the	  degree	  of	  cyanosis	  
that	  is	  often	  caused	  by	  the	  mixing	  of	  deoxygenated	  blood	  intended	  for	  the	  
pulmonary	  circulation	  with	  oxygenated	  blood	  intended	  for	  the	  systemic	  circulation.	  	  
In	  addition,	  rare	  congenital	  defects	  resulting	  in	  stenosis	  of	  the	  great	  vessels	  such	  as	  
midaortic	  syndrome	  (MOS)	  are	  associated	  with	  significant	  morbidity	  and	  mortality	  







Synthetic	  Vascular	  Grafts:	  
The	  clinical	  link	  between	  CVD,	  CHD,	  and	  PAD	  is	  the	  need	  for	  
revascularization	  procedures.	  	  Currently,	  native	  vessels	  represent	  the	  gold	  standard	  
for	  revascularization.	  	  Even	  so,	  commonly	  used	  graft	  vessels	  such	  as	  the	  great	  
saphenous	  vein	  have	  a	  39%	  stenosis	  rate	  secondary	  to	  intimal	  hyperplasia	  by	  10	  
years	  after	  implant.5	  	  Moreover,	  such	  autologous	  grafts	  are	  not	  always	  an	  option	  due	  
to	  limited	  availability	  and	  concurrent	  disease.	  	  Synthetic	  alternatives	  such	  as	  
(poly)tetrafluoroethylene	  (Gortex®,	  W.L.	  Gore	  &	  Associates,	  Newark,	  DE)	  and	  
(poly)ethylene	  terephthalate	  (Dacron®,	  Dupont,	  Wilmington,	  DE)	  have	  several	  
limitations,	  including	  innate	  thrombogencity,	  risk	  of	  infection,	  and	  aneurysm	  
formation.6	  In	  the	  pediatric	  population,	  synthetic	  grafts	  are	  further	  limited	  by	  their	  
lack	  of	  growth	  potential.7	  	  
Notable	  examples	  of	  the	  limitations	  of	  synthetic	  grafts	  in	  the	  pediatric	  
population	  include	  single	  ventricle	  physiology	  CHD	  and	  midaortic	  syndrome.	  	  The	  
standard	  of	  care	  for	  correction	  of	  single	  ventricle	  physiology	  CHD	  is	  a	  staged	  
surgical	  reconstructive	  operation	  known	  as	  the	  Fontan	  procedure.	  	  Classically,	  a	  
Glenn	  shunt	  (a	  superior	  vena	  cava	  to	  right	  pulmonary	  artery	  anastomosis)	  is	  created	  
followed	  by	  a	  by	  a	  proximal	  right	  pulmonary	  artery	  to	  right	  atrium	  anastomosis,	  
thus	  bypassing	  the	  defective	  ventricle.8	  	  Overtime	  this	  procedure	  has	  evolved	  and	  
the	  second	  stage	  is	  now	  performed	  with	  an	  extracardiac	  conduit-­‐total	  
cavopulmonary	  connection	  (EC	  TCPC),	  often	  created	  using	  a	  synthetic	  conduit	  that	  
connects	  the	  inferior	  vena	  cava	  (IVC)	  to	  the	  right	  pulmonary	  artery.8,9	  Use	  of	  an	  EC	  
TCPC	  avoids	  atrial	  manipulation,	  which	  has	  been	  shown	  to	  reduce	  the	  incidence	  of	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intractable	  arrhythmias	  compared	  to	  the	  classic	  Fontan	  operation.10	  	  Use	  of	  the	  
Fontan	  procedure	  has	  significantly	  improved	  outcomes	  for	  patients	  with	  single	  
ventricle	  cardiac	  anomalies	  resulting	  in	  a	  73%	  survival	  rate	  at	  15	  years.	  	  In	  contrast,	  
these	  defects	  are	  associated	  with	  a	  70%	  mortality	  rate	  within	  the	  first	  year	  of	  life	  if	  
left	  untreated.11,12	  Despite	  improvement,	  there	  remains	  significant	  long	  term	  
morbidity	  associated	  with	  synthetic	  conduits.	  13	  	  The	  lack	  of	  growth	  potential	  in	  
synthetic	  grafts	  results	  in	  delayed	  treatment	  and	  graft	  oversizing,	  both	  of	  which	  
increase	  complications	  and	  impair	  growth	  and	  development	  of	  the	  patient.14-­‐17	  
	   Similarly,	  MOS	  is	  a	  rare	  condition	  within	  the	  pediatric	  population	  that	  is	  
characterized	  by	  severe	  narrowing	  of	  the	  abdominal	  aorta	  with	  or	  without	  
involvement	  of	  the	  renal	  and	  mesenteric	  vessels.	  	  It	  is	  associated	  with	  severe	  
hypertension;	  without	  intervention	  it	  is	  generally	  fatal	  between	  30	  and	  40	  years	  of	  
age.3,4	  Although	  MOS	  may	  be	  associated	  with	  multiple	  etiologies,	  treatment	  
universally	  necessitates	  restoration	  of	  distal	  blood	  flow	  to	  the	  kidneys	  and	  lower	  
extremities.18	  Past	  treatments	  have	  included	  angioplasty,	  bypass	  grafting,	  and	  patch	  
aortoplasty.19	  	  As	  with	  the	  modified	  Fontan	  procedure,	  these	  treatments	  have	  been	  
limited	  by	  the	  use	  of	  synthetic	  materials,	  which	  due	  to	  a	  lack	  of	  growth	  potential	  
require	  initial	  oversizing	  or	  multiple	  procedures	  throughout	  the	  development	  of	  the	  
patient.	  	  Ideally,	  autologous	  tissue	  that	  could	  grow	  with	  the	  child	  to	  adulthood	  
would	  be	  used	  to	  replace	  the	  coarcted	  portion	  of	  aorta.	  	  	  Recently,	  a	  tissue	  expander	  
has	  been	  used	  to	  generate	  a	  lengthy	  segment	  of	  aortic	  tissue	  for	  this	  purpose;	  
however,	  this	  procedure	  requires	  a	  9-­‐month	  period	  of	  tissue	  expansion.20	  	  As	  with	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single	  ventricle	  physiology	  CHD,	  delayed	  treatment	  is	  associated	  with	  poorer	  
outcomes	  and	  increased	  morbidity.	  
	  
A	  potential	  solution-­‐	  Tissue	  Engineered	  Vascular	  Grafts:	  
To	  address	  the	  limitations	  and	  complications	  of	  current	  technologies,	  tissue	  
engineered	  vascular	  grafts	  (TEVGs)	  have	  emerged	  as	  an	  alternative	  source	  of	  
vascular	  conduits.	  	  In	  its	  most	  simplified	  form	  vascular	  tissue	  engineering	  is	  the	  
implantation	  of	  a	  biodegradable	  scaffold—seeded	  with	  cells	  or	  unseeded—within	  a	  
living	  host.	  	  The	  biodegradable	  scaffold	  initially	  serves	  as	  a	  site	  of	  cell	  attachment	  
and	  neotissue	  formation	  while	  acting	  as	  a	  passive	  conduit	  for	  blood	  flow.	  	  Over	  time,	  
the	  biodegradable	  scaffold	  loses	  mechanical	  strength	  while	  the	  neotissue	  begins	  to	  
develop	  mechanical	  strength.	  	  The	  culmination	  is	  a	  neovascular	  conduit	  composed	  
entirely	  of	  autologous	  tissue	  with	  an	  intima,	  media,	  and	  adventitia	  in	  the	  absence	  of	  
any	  scaffold	  material.21	  	  	  
Recently,	  TEVGs	  composed	  of	  a	  (poly)glycolic	  acid	  scaffold	  coated	  with	  a	  
50:50	  copolymer	  of	  ε-­‐caprolactone	  and	  L-­‐lactide	  (P[PC/LA])	  and	  seeded	  with	  bone	  
marrow	  derived	  mononuclear	  cells	  have	  been	  developed	  for	  the	  venous	  circulation.	  
These	  grafts	  were	  evaluated	  in	  the	  second	  stage	  of	  the	  Fontan	  procedure	  as	  EC	  TCPC	  
in	  a	  pilot	  clinical	  trial	  in	  Japan	  by	  Dr.	  Toshiharu	  Shinoka	  and	  colleagues	  with	  
excellent	  results.22-­‐25	  All	  implanted	  grafts	  remained	  patent	  without	  aneurysmal	  
dilatation,	  graft	  infection,	  graft	  rupture,	  or	  ectopic	  calcification;	  however,	  the	  
primary	  complication	  encountered	  was	  stenosis	  in	  6	  out	  of	  25	  patients.	  	  Three	  of	  
these	  patients	  required	  balloon	  angioplasty	  and	  one	  required	  balloon	  angioplasty	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with	  stent	  placement.	  	  All	  patients	  were	  successfully	  treated	  and	  there	  was	  no	  graft	  
related	  mortality.26	  In	  order	  to	  better	  understand	  the	  molecular	  mechanisms	  and	  
mechanics	  behind	  TEVG	  development,	  a	  murine	  model	  was	  developed	  for	  both	  
venous	  and	  arterial	  grafts.27	  	  This	  murine	  model	  has	  been	  extensively	  validated	  in	  
the	  venous	  circulation	  where	  seeded	  grafts	  faithful	  recapitulate	  the	  results	  seen	  in	  
the	  aforementioned	  pilot	  clinical	  trial.28-­‐32	  	  	  
Development	  of	  a	  TEVG	  for	  the	  arterial	  circulation	  has	  been	  more	  difficult	  
due	  to	  the	  relatively	  demanding	  high-­‐pressure	  pulsatile	  arterial	  flow.	  	  When	  
scaffolds	  similar	  to	  those	  used	  in	  the	  pilot	  clinical	  study	  are	  implanted	  within	  the	  
arterial	  circulation	  rather	  than	  the	  venous	  circulation	  they	  typically	  rupture	  within	  
ten	  days,	  presumably	  due	  to	  inadequate	  neotissue	  development	  in	  the	  context	  of	  
rapid	  scaffold	  degradation	  and	  high	  arterial	  pressures.	  	  Instead,	  TEVGs	  composed	  of	  
(poly)lactic	  acid	  (PLA)	  scaffolds	  are	  used	  due	  to	  their	  relatively	  slower	  degradation	  
rate.	  	  While	  these	  grafts	  develop	  mild	  dilation,	  they	  remain	  patent	  without	  rupture	  
through	  one	  year	  of	  implantation.	  	  In	  addition	  the	  neovessel	  developed	  endothelial	  
cell	  layers	  and	  concentric	  smooth	  muscle	  layers.27,33	  
	  
Growth	  and	  Remodeling-­‐	  Exploring	  vascular	  biomechanics:	  
Arteries	  respond	  to	  changes	  in	  mechanical	  loading	  through	  a	  process	  of	  
growth	  (changes	  in	  mass)	  and	  remodeling	  (changes	  in	  structure)	  that	  tends	  to	  
maintain	  nearly	  constant	  the	  preferred	  levels	  of	  stress.	  	  	  Termed	  “mechanical	  
homeostasis,”	  these	  mechanobiologic	  responses	  occur	  at	  multiple	  levels,	  from	  whole	  
tissue	  down	  to	  cellular	  and	  subcellular	  structures.34	  	  	  For	  example,	  large	  arteries	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regulate	  their	  lumen	  via	  endothelial	  cell	  –	  smooth	  muscle	  cell	  responses	  that	  
maintain	  a	  wall	  shear	  stress	  of	  approximately	  1.5Pa.35	  	  Similarly,	  fibroblasts	  
cultured	  in	  3D	  collagen	  matrices	  generate	  an	  endogenous	  tensile	  stress	  and	  
subsequently	  relax	  or	  contract	  to	  maintain	  this	  stress	  secondary	  to	  exogenous	  
mechanical	  loading	  or	  unloading	  of	  the	  matrices.36	  	  Indeed,	  even	  pathologic	  
situations	  such	  as	  aneurysms,	  which	  alter	  the	  hemodynamic	  loading,	  result	  in	  
significant	  remodeling	  of	  extracellular	  matrix,	  via	  increased	  matrix	  
metalloproteinase	  (MMP)	  activity	  and	  synthesis	  of	  collagens	  type	  I	  and	  III,	  which	  
again	  appears	  to	  seek	  to	  return	  wall	  stresses	  toward	  normal	  levels.37-­‐39	  
Nevertheless,	  the	  mechanobiology	  of	  neotissue	  formation	  has	  not	  been	  well	  
explored	  in	  the	  field	  of	  vascular	  tissue	  engineering,	  wherein	  the	  focus	  is	  generally	  on	  
gross	  mechanical	  metrics	  (e.g.,	  burst	  pressure)	  or	  molecular	  biology	  (e.g.,	  cytokine	  
activity)	  independent	  of	  mechanical	  stimuli.	  	  Because	  a	  degradable	  polymeric	  
scaffold,	  such	  as	  a	  TEVG,	  can	  exhibit	  changing	  mechanical	  properties	  that	  result	  in	  
changes	  in	  the	  hemodynamics	  and	  the	  axial	  loads	  exerted	  on	  the	  host	  vessel,	  there	  is	  
a	  pressing	  need	  to	  correlate	  the	  evolving	  cell	  and	  matrix	  biology	  with	  the	  evolving	  
mechanics.	  	  Indeed,	  the	  radical	  change	  in	  mechanical	  environment	  that	  an	  
interpositional	  TEVG	  introduces	  necessitates	  evaluation	  of	  the	  adaptive	  response	  of	  







Questions	  remaining	  to	  be	  answered:	  
An	  understating	  of	  the	  mechanobiology	  of	  native	  arteries	  has	  led	  to	  the	  
development	  of	  computational	  models	  that	  predict	  arterial	  growth	  and	  remodeling	  
(G&R)	  in	  response	  to	  changes	  in	  blood	  pressure,	  flow,	  and	  axial	  loading.40-­‐42	  
Evaluation	  of	  TEVGs	  implanted	  in	  the	  venous	  circulation	  has	  demonstrated	  evolving	  
mechanical	  properties	  of	  TEVGs	  that	  approach	  that	  of	  native	  tissue	  by	  24	  weeks.43	  	  	  
An	  associated	  modeling	  study	  by	  Miller	  and	  colleagues	  captures	  salient	  aspects	  of	  
the	  biomechanics	  of	  the	  aforementioned	  venous	  remodeling.44	  	  	  Likewise,	  a	  G&R	  
framework	  has	  been	  introduced	  to	  simulate	  TEVGs	  grown	  in	  bioreactors.45	  	  As	  of	  
yet,	  there	  is	  insufficient	  experimental	  data	  with	  which	  to	  evaluate	  the	  mechanical	  
development	  of	  arterial	  TEVGs	  or	  with	  which	  to	  generate	  computational	  models.	  	  
Were	  such	  computational	  models	  to	  be	  developed,	  they	  could	  be	  a	  powerful	  tool,	  
allowing	  for	  refinement	  and	  optimization	  of	  TEVGs	  in	  silico	  prior	  to	  more	  time	  















Statement	  of	  Purpose:	  
	  
This	  project	  was	  designed	  to	  elucidate	  the	  mechanics	  by	  which	  arterial	  TEVGs	  
develop	  and	  remodel.	  	  Specific	  emphasis	  was	  placed	  on	  comparing	  the	  mechanical	  





Bone	  marrow-­‐derived	  mononuclear	  cell	  seeded	  TEVGs	  develop	  mechanical	  
properties	  mimicking	  those	  of	  native	  arteries	  as	  their	  initial	  scaffold	  material	  is	  
replaced	  by	  the	  cellular	  and	  extracellular	  components	  of	  the	  arterial	  wall.	  
	  
Specific	  Aims:	  
1)	  Track	  biomechanical	  changes	  that	  occur	  as	  the	  TEVGs	  develop	  in	  the	  arterial	  
circulation.	  











This	   study	  was	   in	   accordance	  with	   the	   institutional	   guidelines	   for	   the	   care	  
and	   use	   of	   laboratory	   animals,	   and	   the	   institutional	   committee	   approved	   the	  
experimental	  procedures	  described	  below.	  
	  
Graft	  Fabrication	  and	  Implantation:	  
	   TEVG	  scaffolds	  were	  constructed	  from	  sheets	  of	  nonwoven	  (poly)lactic	  acid	  
(PLA;	  Concordia	  Fibers,	  Coventry,	  RI)	  that	  were	  rolled	  into	  a	  tube	  and	  sealed	  with	  a	  
50:50	  copolymer	  of	  ε-­‐(poly)caprolactone	  and	  L-­‐(poly)lactide	  (P[PC/LA];	  Absorbable	  
Polymers	  International,	  Birmingham,	  AL)	  using	  a	  dual	  cylinder	  chamber	  molding	  
system.27	  	  Briefly,	  a	  5.0mm	  x	  6.0mm	  PLA	  felt	  section	  was	  introduced	  through	  the	  
inlet	  of	  the	  dual	  chamber	  system,	  while	  a	  23-­‐gauge	  stainless	  steel	  needle	  was	  then	  
introduced	  into	  the	  opposing	  end	  to	  maintain	  the	  inner	  lumen.	  	  Afterward	  the	  50:50	  
P[PC/LA]	  dissolved	  in	  glacial	  acetic	  acid	  was	  introduced	  followed	  by	  snap-­‐freezing	  
at	  -­‐20°C	  for	  30	  minutes.	  The	  scaffold	  within	  the	  dual	  chamber	  device	  was	  
lyophilized	  for	  24	  hours	  to	  eliminate	  solvents.	  	  Scaffolds	  were	  removed	  from	  the	  
dual	  chamber	  device	  and	  trimmed	  to	  ~3.5mm	  in	  length,	  with	  an	  inner	  diameter	  of	  
~700μm	  and	  wall	  thickness	  of	  ~290μm	  (Fig.	  1).	  	  	  
Prior	  to	  implantation,	  bone	  marrow	  derived	  mononuclear	  cells	  (BM-­‐MNCs)	  
were	  harvested	  from	  the	  tibia,	  femur,	  and	  humerus	  of	  8-­‐10	  week	  old	  male	  C57BL/6	  
mice	  and	  isolated	  via	  density-­‐gradient	  centrifugation	  using	  histopque-­‐1077	  (Sigma).	  	  
The	  isolated	  cells	  were	  used	  to	  statically	  seed	  the	  scaffolds	  (~1x106	  cells/scaffold)	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by	  pipetting	  concentrated	  cells	  in	  media	  (RPMI-­‐1640;	  Gibco,	  Inc.)	  into	  the	  inner	  
lumen	  and	  outer	  surface	  of	  the	  scaffold.28	  	  Cells	  were	  incubated	  in	  RPMI-­‐1640	  for	  12	  
hours	  at	  37°C	  prior	  to	  implantation.	  Ethan	  Dean	  and	  Kevin	  Rocco	  aided	  the	  author	  in	  
the	  bone	  marrow	  harvest	  and	  isolation	  of	  BM-­‐MNCs.	  
	   The	  cell-­‐seeded	  TEVGs	  were	  implanted	  as	  interpositional	  grafts	  in	  the	  
infrarenal	  abdominal	  aorta	  (IAA)	  in	  50	  female	  CB57BL/6	  mice	  between	  8	  and	  10	  
weeks	  of	  age.	  	  Implantation	  was	  accomplished	  using	  a	  sterile	  microsurgical	  
technique.	  	  Mice	  anesthetized	  with	  a	  peritoneal	  injection	  of	  ketamine	  and	  xylazine	  
were	  placed	  in	  the	  supine	  position	  and	  opened	  with	  an	  abdominal	  midline	  incision.	  	  
The	  IAA	  was	  exposed	  under	  magnification,	  cross-­‐clamped,	  and	  excised.	  Scaffolds	  
were	  inserted	  as	  interposition	  grafts	  using	  a	  running	  10-­‐0	  nylon	  suture	  for	  the	  end-­‐
to-­‐end	  proximal	  and	  distal	  anastomoses.	  	  All	  animal	  surgeries	  were	  performed	  by	  
Dr.	  Tai	  Yi.	  	  The	  animals	  were	  recovered	  from	  surgery	  and	  maintained	  without	  the	  
use	  of	  any	  anti-­‐coagulation	  or	  anti-­‐platelet	  therapy.	  27	  	  	  
	  
Scanning	  Electron	  Microscopy:	  	  
Representative	  scaffolds	  were	  cut	  into	  0.5mm	  thick	  cross-­‐sections	  and	  imaged	  on	  a	  
FEI	  XL-­‐30	  scanning	  electron	  microscope	  (SEM)	  [Hillsboro,	  OR].	  Lumen	  diameters	  
and	  wall	  thickness	  were	  measured	  from	  high	  magnification	  SEM	  images.	  	  














Figure	  1:	  Scanning electron microscopic image of a 
representative pre-implant TEVG showing both a cross-




In	  vivo	  Ultrasound:	  
TEVG	  patency,	  wall	  thickness,	  and	  luminal	  diameter	  were	  assessed	  in	  vivo	  while	  
mice	  were	  sedated	  with	  isoflurane	  using	  high	  frequency	  ultrasound	  system	  (Vevo	  
770,	  Visualsonics,	  Toronto,	  Canada)	  with	  an	  RMV-­‐704	  transducer.	  	  	  
	  
Biaxial	  Mechanical	  Testing:	  
	   At	  3	  and	  7	  months,	  TEVGs	  were	  harvested	  for	  biaxial	  mechanical	  testing.	  	  
Following	  anesthesia	  using	  a	  peritoneal	  injection	  of	  ketamine	  and	  xylazine,	  a	  
continuous	  vascular	  segment	  was	  harvested	  containing	  the	  TEVG	  as	  well	  as	  native	  
IAA	  both	  proximally	  and	  distally.	  	  The	  author	  along	  with	  Ramak	  Khosravi	  preformed	  
all	  explanations.	  	  Prior	  to	  explant,	  India	  ink	  was	  use	  to	  mark	  the	  proximal	  IAA,	  
proximal	  TEVG,	  distal	  TEVG,	  and	  distal	  IAA.	  In	  order	  to	  ensure	  adequate	  
pressurization	  and	  to	  prevent	  leakage	  during	  in	  vitro	  testing,	  branching	  vessels	  were	  
identified	  and	  ligated.	  	  Photographs	  were	  taken	  to	  record	  the	  positions	  of	  the	  ink	  
marks	  before	  explant	  and	  10	  minutes	  thereafter.	  	  Distances	  between	  marks	  were	  
calculated	  with	  ImageJ	  software	  and	  used	  to	  determine	  the	  ratio	  between	  loaded	  
and	  unloaded	  length,	  also	  known	  as	  in	  vivo	  axial	  stretch.	  	  After	  explant,	  the	  
composite	  vessel	  was	  cannulated	  and	  secured	  to	  custom	  drawn	  micropipettes	  with	  
6-­‐0	  suture.	  	  The	  cannulated	  vessels	  were	  placed	  within	  a	  custom	  computer-­‐
controlled	  biaxial	  testing	  device	  described	  by	  Gleason	  et	  al.	  46	  The	  testing	  chamber	  
was	  filled	  with	  Hank’s	  balanced	  salt	  solution,	  including	  calcium	  chloride	  and	  










Figure	  2:	  	  Schematic drawing of the biaxial mechanical testing device.  (a) The 
composite vessel, consisting of the proximal IAA-TEVG-distal IAA, was cannulated 
using custom micropipettes.  Luminal flow and pressure were controlled through the 
micropipettes and axial stretch was controlled via paired stepper motors; pressure 
and force were monitored with standard transducers. (b) Representative image of a 
TEVG mounted within the device with the video camera used for measuring 
diameter focused on the TEVG.  (c) Representative image of a TEVG within the 
device with the camera focused on the proximal IAA.  Outer diameter is indicated 




The	  composite	  vessels	  (proximal	  IAA—TEVG—distal	  IAA)	  were	  placed	  
within	  the	  device	  at	  their	  unloaded	  state	  and	  initial	  unloaded	  dimensions	  were	  
recorded.	  	  Prior	  to	  testing,	  vessels	  were	  allowed	  to	  equilibrate	  at	  80	  mmHg	  for	  15	  
minutes	  at	  their	  measured	  in	  vivo	  axial	  stretch.	  	  The	  vessels	  were	  then	  
preconditioned	  at	  this	  axial	  stretch	  by	  4	  cycles	  of	  pressurization	  from	  10	  to	  100	  
mmHg	  at	  a	  rate	  of	  ~2	  mmHg/second.	  	  Following	  preconditioning,	  unloaded	  
dimensions	  were	  measured	  again;	  increases	  in	  dimensions	  relative	  to	  those	  taken	  
prior	  to	  preconditioning	  and	  equilibration	  were	  minimal.	  The	  in	  vivo	  axial	  stretch	  of	  
the	  composite	  vessel	  was	  also	  estimated	  in	  vitro	  by	  identifying	  the	  axial	  stretch	  at	  
which	  axial	  force	  remained	  nearly	  constant	  in	  response	  to	  changes	  in	  luminal	  
pressure.47	  	  This	  estimation	  was	  accomplished	  by	  measuring	  axial	  force	  at	  pressures	  
of	  50	  mmHg,	  60	  mmHg,	  80	  mmHg,	  and	  100	  mmHg	  at	  axial	  stretches	  slightly	  above	  
and	  below	  the	  value	  of	  axial	  stretch	  measured	  from	  the	  India	  ink	  dots.	  	  With	  the	  
camera	  focused	  on	  the	  central	  region	  of	  the	  TEVG,	  pressure-­‐diameter	  testing	  
consisted	  of	  cyclic	  pressurization	  from	  10	  to	  100	  mmHg	  at	  the	  experimentally	  
determined	  in	  vivo	  axial	  stretch	  and	  at	  ±5%	  this	  value.	  	  Pressure-­‐diameter	  testing	  
was	  repeated	  with	  the	  camera	  focused	  on	  the	  proximal	  IAA.	  	  Luminal	  pressure,	  axial	  
force,	  outer	  diameter,	  and	  overall	  axial	  length	  were	  measured	  continually	  
throughout	  testing	  using	  a	  custom	  LabView	  program.	  
	  
Histology	  and	  Immunohistochemistry:	  
	   Samples	  explanted	  at	  3	  and	  7	  months	  were	  fixed	  in	  10%	  neutral	  buffered	  
formalin	  for	  24	  hours	  and	  embedded	  in	  paraffin.28	  	  Samples	  were	  stained	  with	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hematoxylin	  and	  eosin	  (H&E),	  Masson’s	  Trichrome	  (TRI),	  picrosirius	  red	  (PSR),	  
Movat’s	  Pentachrome	  (MOV),	  and	  Verhoeff-­‐Van	  Gieson	  (VVG).	  	  VVG	  and	  TRI	  stained	  
samples	  were	  analyzed	  with	  a	  custom	  Matlab	  code	  that	  quantifies	  pixels	  associated	  
with	  elastin	  and	  collagen,	  respectively.	  	  The	  Matlab	  code	  was	  developed	  by	  Matthew	  
Bersi.	  	  A	  similar	  program	  was	  used	  to	  calculate	  the	  relative	  distribution	  of	  large	  and	  
small	  collagen	  fibers	  on	  PSR-­‐stained	  sections.	  	  Unstained	  samples	  used	  for	  
immunohistochemistry	  (IHC)	  were	  rehydrated	  and	  blocked	  for	  endogenous	  
peroxidase	  activity;	  antibodies	  included	  those	  for	  CD31	  (endothelial	  cell	  marker;	  
Abcam),	  α-­‐smooth	  muscle	  actin	  (Dako),	  calponin	  (Abcam),	  F4/80	  (marker	  for	  
mouse	  macrophages;	  AbD	  Serotec),	  MMP-­‐2	  (Abcam),	  MMP-­‐9	  (Abcam),	  collagen	  type	  
I	  (Abcam),	  and	  collagen	  type	  III	  (Abcam).	  	  Antibody	  binding	  was	  detected	  using	  
biotinylated	  secondary	  antibodies,	  followed	  by	  binding	  of	  streptavidin	  horseradish	  
peroxidase31	  by	  the	  author	  with	  assistance	  from	  Ethan	  Dean.	  	  For	  
immunofluorescence	  detection,	  tropoelastin	  (elastin	  marker;	  Abcam)	  was	  used	  with	  
subsequent	  4′,6-­‐diamidino-­‐2-­‐phenylindole	  nuclear	  counterstaining28	  and	  performed	  
by	  the	  author	  with	  assistance	  from	  Angela	  Huang.	  
	  
Partial	  Collagenase	  Treatment:	  
Similar	  to	  Collins	  et	  al.48,	  the	  lumen	  of	  the	  unloaded	  composite	  vessels,	  
containing	  proximal	  IAA,	  TEVG,	  and	  distal	  IAA,	  was	  perfused	  with	  collagenase	  (1035	  
U/ml;	  Worthington	  Biochemical	  Corporation).	  	  This	  collagenase,	  which	  was	  tinted	  
brown,	  remained	  intraluminal	  until	  collagen	  degradation	  allowed	  slow	  leaking	  from	  
the	  IAA	  into	  the	  testing	  bath.	  	  At	  this	  point	  the	  mechanical	  integrity	  of	  the	  native	  IAA	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was	  compromised,	  but	  the	  TEVG	  could	  still	  be	  pressurized.	  	  The	  TEVG	  was	  thus	  
isolated	  immediately	  from	  the	  IAA,	  cannulated,	  washed	  with	  phosphate	  buffered	  
saline	  (PBS),	  and	  subjected	  again	  to	  cyclic	  pressure-­‐diameter	  testing	  at	  its	  
cannulated	  stretch	  though	  a	  pressure	  range	  of	  10	  to	  100	  mmHg.	  
	  
Elastase	  Treatment:	  
	   Similar	  to	  Ferruzzi	  et	  al.	  49	  and	  Collins	  et	  al.	  48,	  the	  lumen	  of	  the	  composite	  
vessels	  was	  perfused	  with	  3	  ml	  of	  elastase	  (7.5	  U/ml;	  Worthington	  Biochemical	  
Corporation)	  while	  maintained	  at	  its	  experimentally	  determined	  in	  vivo	  axial	  
stretch.	  	  The	  elastase	  perfusion	  was	  maintained	  at	  80	  mmHg	  for	  30	  minutes,	  after	  
which	  the	  dilatation	  of	  the	  proximal	  and	  distal	  IAA	  remained	  unchanged	  and	  any	  
remaining	  elastase	  was	  washed	  out	  with	  media.	  	  Pressure-­‐diameter	  testing	  was	  
performed	  again	  on	  the	  composite	  vessel	  (i.e.,	  TEVG	  and	  proximal	  IAA)	  at	  the	  
original	  in	  vivo	  axial	  stretch	  and	  ±5%	  this	  value.	  
	  
Statistical	  Analysis:	  
	   Pressure-­‐diameter	  curves	  were	  normalized	  by	  dividing	  all	  outer	  diameter	  
measurements	  by	  the	  minimum	  diameter	  at	  a	  given	  axial	  stretch	  and	  presented	  as	  
mean	  ±	  standard	  error	  of	  the	  mean	  (SEM).	  	  All	  other	  data	  were	  represented	  as	  mean	  
±	  standard	  deviation	  (SD).	  	  Ultrasound	  data	  collected	  at	  multiple	  time	  points	  were	  
analyzed	  by	  using	  two-­‐way	  analysis	  of	  variance	  (ANOVA)	  with	  repeated	  measures,	  
followed	  by	  Sidak’s	  multiple	  comparisons	  test.	  	  All	  other	  data	  between	  groups	  were	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analyzed	  using	  either	  a	  Student’s	  t-­‐test	  or	  one-­‐way	  ANOVA,	  followed	  by	  Tukey’s	  
multiple	  comparisons	  test.	  	  P-­‐values	  <	  0.05	  were	  considered	  statistically	  significant	  	  
	  
Results:	  
In	  vivo	  Monitoring:	  	  
	   Fourteen	  of	  the	  fifty	  mice	  implanted	  (28%)	  were	  euthanized	  or	  died	  
prematurely	  due	  to	  graft	  related	  complications	  (Fig.	  3	  a	  and	  b).	  	  Three	  distinct	  
periods	  of	  failure	  were	  observed:	  (Early)	  within	  hours	  post-­‐implant	  due	  to	  
complications	  of	  micro-­‐surgery	  (2%);	  (Intermediate)	  between	  5	  and	  14	  days	  due	  to	  
failure	  of	  the	  P[PC/LA]	  sealant	  with	  resulting	  rupture	  along	  the	  seam	  on	  the	  scaffold	  
(18%);	  (Late)	  between	  14	  days	  and	  42	  days	  due	  to	  rupture	  of	  the	  wall	  of	  the	  TEVG	  
(8%).	  	  No	  graft	  related	  mortality	  occurred	  after	  42	  days	  and	  overall	  survival	  was	  
72%.	  	  On	  Doppler	  ultrasound,	  surviving	  mice	  had	  an	  increased	  luminal	  diameter	  
within	  the	  TEVG	  when	  compared	  to	  native	  aorta,	  which	  was	  consistent	  with	  slight	  
over-­‐sizing	  of	  TEVG	  lumen	  at	  implantation.	  	  Wall	  thickness	  of	  TEVGs	  was	  also	  
significantly	  greater	  than	  native	  aorta.	  	  Over	  the	  experimental	  time	  course,	  the	  
TEVGs	  demonstrated	  stability	  in	  both	  luminal	  diameter	  and	  wall	  thickness	  without	  
any	  statistically	  significant	  changes	  between	  2	  and	  24-­‐weeks	  (Fig.	  3).	  	  	  
	  
Biaxial	  Mechanical	  Testing:	  
	   A	  statistically	  significant	  difference	  was	  observed	  between	  axial	  stretch	  of	  
the	  TEVG	  and	  IAA	  at	  both	  3	  and	  7	  months;	  however,	  no	  difference	  was	  observed	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between	  time	  points	  (Fig.	  4	  a	  and	  b).	  	  Pressure-­‐diameter	  curves	  of	  mounted	  
composite	  vessels	  demonstrated	  a	  lack	  of	  compliance	  in	  TEVG	  compared	  to	  
proximal	  IAA	  over	  a	  pressure	  range	  of	  10	  to	  100	  mmHg	  at	  both	  times	  (Fig.	  5).	  	  Note,	  
too,	  that	  the	  composite	  vessel	  maintained	  nearly	  constant	  axial	  force	  during	  






Figure	  3:	  	  Survival and in vivo evaluation of TEVGs.  (a) Survival curve 
demonstrating three distinct periods of mortality: early, intermediate, and late. (b) 
Percentage of long-term survival and mortality.   (c) Representative Doppler 
ultrasound images of TEVGs at various times, which show consistent graft 
patency.  (d) TEVG luminal diameter as measured by Doppler ultrasound (n=12). 
(e) TEVG wall thickness as measured by Doppler ultrasound (n =12).  Data in 














Figure	  4:	  Evaluation of axial stretch and force.  (a) Representative image of 
TEVG at explant.  Note: India ink marked proximal IAA, proximal TEVG, 
distal TEVG, and distal IAA. (b) Axial stretch ratio of the loaded and 
unloaded state measured at 3 (n=9) and 7 (n=6) months expressed as mean ± 
SD.  (c) Axial Force during pressure-diameter curves at 3 and 7 months at in 
vivo axial stretch expressed as mean ± SEM. * p <0.05; NS indicates 


























Figure	  5:	  	  Pressure-diameter curves at (a) 3 months 
(n=9) and (b) 7 months (n=6) comparing proximal 
IAA and TEVG at in vivo axial stretches.  Data in 







TEVGs	  develop	  endothelial	  cell	  lining	  and	  smooth	  muscle	  layers:	  
	   Histologic	  analysis	  revealed	  extensive	  cellular	  infiltration	  within	  the	  TEVGs	  
(Fig.	  6).	  TEVGs	  had	  increased	  luminal	  diameter	  and	  wall	  thickness	  relative	  to	  native	  
IAA	  harvested	  from	  aged-­‐matched	  controls.	  	  The	  difference	  in	  luminal	  area	  
appeared	  more	  pronounced	  on	  histologic	  staining	  than	  on	  ultrasound,	  likely	  due	  
increased	  recoil	  and	  dehydration	  effects	  during	  fixation	  in	  the	  native	  tissue.	  	  H&E	  
staining	  showed	  abundant	  residual	  polymer	  at	  both	  times,	  which	  could	  be	  isolated	  
and	  quantified	  under	  polarized	  light	  due	  to	  innate	  birefringence	  (Fig.	  8r).	  
Immunohistochemical	  staining	  for	  CD31	  indicated	  development	  of	  a	  luminal	  
endothelial	  layer,	  while	  staining	  for	  calponin	  and	  α-­‐smooth	  muscle	  actin	  indicated	  
the	  presence	  of	  smooth	  muscle	  cells	  within	  the	  wall.	  	  Note	  that	  positive	  staining	  for	  
calponin	  occurred	  predominantly	  in	  concentric	  neotissue	  layers	  between	  the	  
polymer	  and	  endothelialized	  lumen.	  	  The	  presence	  of	  extensive	  macrophages	  on	  
F4/80	  staining	  suggested	  an	  inflammatory	  component	  to	  the	  remodeling	  process,	  
which	  was	  further	  characterized	  by	  the	  positive	  staining	  of	  MMP-­‐2	  and	  MMP-­‐9	  at	  3	  















Figure	  6:	  Morphologic evaluation of mouse IAA and TEVG at 3 and 7 months post-
implantation.  Native mouse IAA stained for (a-e): H&E (cell nuclei), CD31 
(endothelial cells (EC)), and SMA and CAL (smooth muscle (SM)). Similarly, TEVG at 
3 months (f-j) and 7 months (k-q) stained for: H&E, CD31, SMA, and CAL. Note the 
abundant residual polymer (P) in the TEVG, with the neotissue (NT) forming along the 
lumen.  Low-magnification photomicrographs are at magnification of 50x.  All other 













Figure	  7:	  	  Evaluation of inflammatory response to TEVG. Native mouse IAA 
stained for (a-c):  F4/80 (mouse macrophage marker), MMP-2, and MMP-9. 
Similarly, TEVG at 3 months (d-f) and 7 months (g-i) stained for F4/80, MMP-2, 





Collagen	  Contributes	  to	  TEVG	  Stiffness:	  	  
Extensive	  deposition	  of	  collagen	  was	  demonstrated	  by	  TRI	  staining	  (Fig	  8).	  	  
Quantification	  of	  pixels	  positive	  for	  collagen	  revealed	  similar	  area	  fractions	  for	  
collagen	  between	  native	  IAA	  and	  TEVG	  at	  both	  3	  and	  7	  months.	  	  PSR,	  which	  provides	  
information	  on	  the	  diameter	  of	  the	  collagen	  fibers,	  revealed	  a	  similar	  pattern	  of	  
distribution	  of	  large	  (red/orange)	  and	  small	  (yellow/green)	  fibers	  between	  native	  
IAA	  and	  TEVG	  at	  both	  low	  and	  high	  light	  exposure	  (Fig.	  9).	  	  The	  low	  light	  exposure	  
was	  used	  to	  focus	  on	  the	  adventitia	  while	  the	  high	  light	  exposure	  was	  used	  to	  focus	  
on	  the	  media.	  	  Collagen	  content	  of	  TEVGs	  was	  further	  characterized	  by	  IHC,	  which	  
revealed	  collagen	  type	  I	  (COL	  I)	  and	  collagen	  type	  III	  (COL	  III)	  throughout	  the	  TEVG	  
wall,	  both	  closely	  associated	  with	  areas	  containing	  residual	  polymer.	  
	   Whereas	  complete	  enzymatic	  degradation	  of	  collagen	  caused	  the	  TEVG	  to	  
leak,	  partial	  treatment	  with	  collagenase	  maintained	  structural	  integrity.	  	  Pressure-­‐
diameter	  testing	  at	  3	  and	  7	  months	  demonstrated	  a	  modest	  increase	  in	  TEVG	  
compliance	  due	  to	  partial	  loss	  of	  collagen,	  hence	  implying	  some	  contribution	  of	  
collagen	  to	  the	  circumferential	  stiffness	  that	  was	  dominated	  by	  polymer	  post-­‐
















Figure	  8:	  Quantification of collagen within TEVG.  Native mouse IAA 
stained with (a-c): TRI, COL I, and COL III. Similarly, TEVG at 3 
months (d-f) and 7 months (g-i) stained for TRI, COL I, and COL III. (j) 
Evaluation of area fraction of collagen within biologically active stained 
tissue for TRI stain.  (k) Evaluation of residual polymer within TEVG at 
3 and 7 months.   All photomicrographs at magnification of 200x.  Data 
in graphs are expressed as mean ± SD (n=4 for all groups; all differences 










Figure	  9:	  Evaluation of collagen fiber size within TEVG.  Native mouse IAA 
stained with (a-b) PSR focused on adventitia (PSR ADV), PSR focused on media 
(PSR MED).  Similarly, TEVG at 3 months (c-d) and 7 months (e-f) stained for 
PSR focused on adventitia and PSR focused on media.  (g) Relative percentage of 
large diameter and small diameter fibers by PSR staining at low light exposure 
(adventitia).  (h) Relative percentage of large diameter and small diameter fibers 
by PSR staining at high light exposure (media).  *p < 0.05	  
33	  
	  
Evaluation	  of	  Elastin:	  
By	  3	  months,	  elastin	  was	  evident	  along	  the	  inner	  circumferential	  layers	  of	  the	  
TEVG	  (Fig.	  10).	  	  Using	  a	  digital	  extraction	  method	  and	  VVG	  staining,	  we	  found	  a	  
significant	  increase	  in	  the	  area	  fraction	  of	  elastin	  between	  3	  and	  7	  months.	  	  
Nevertheless,	  the	  elastin	  fraction	  was	  significantly	  lower	  than	  native	  at	  both	  times.	  	  
In	  addition,	  the	  elastic	  fibers	  in	  the	  TEVG	  appeared	  thinner	  and	  less	  organized	  than	  
those	  in	  native	  tissue,	  most	  notably	  on	  immunohistochemical	  staining	  of	  
tropoelastin	  (Fig.	  11).	  At	  both	  3	  and	  7	  months,	  treatment	  with	  elastase	  did	  not	  
significantly	  change	  TEVG	  compliance	  (Fig.	  10).	  Conversely,	  the	  elastase	  did	  
decrease	  the	  compliance	  of	  the	  proximal	  IAA,	  which	  then	  mimicked	  the	  appearance	  

























Figure	  10:	  Pressure-diameter curves for 
untreated (n=4), elastase treated (n=2), and 
partial-collagenase (n=2) treated TEVGs at (a) 3 
months and (b) 7 months.  Data in graphs are 










Figure	  11:	  	  Evaluation of elastin fiber development within 
TEVGs.  Native mouse IAA stained for (a and b): VVG  (elastic 
fibers) and TRO.  Similarly, TEVG at 3 months (c and d) and 7 
months (e and f) stained for VVG and TRO.  (g) Area fraction of 
elastin within biologically active stained tissue by VVG stain 
(n=4 for all groups).  VVG and TRO photomicrographs are at a 
magnification of 200x and 300x respectively. Data in graphs are 




	   This	  study	  was	  designed	  to	  assess	  evolving	  biomechanical	  properties	  of	  
TEVGs	  implanted	  in	  the	  arterial	  circulation	  and	  to	  begin	  to	  elucidate	  
mechanobiological	  principles	  that	  affect	  vascular	  neotissue	  formation.	  Within	  the	  
past	  five	  years,	  several	  arterial	  grafts	  have	  been	  evaluated	  in	  both	  mouse	  and	  rat	  
models.33,50-­‐52	  While	  the	  field	  has	  shown	  rapid	  advancement	  in	  the	  creation	  of	  
autologous	  blood	  vessels	  with	  the	  potential	  to	  function	  as	  vascular	  grafts,	  little	  is	  
known	  about	  the	  mechanical	  properties	  of	  these	  engineered	  constructs	  as	  they	  
mature	  within	  their	  host	  recipients.	  	  It	  is	  hoped	  that	  an	  understanding	  of	  
mechanobiologic	  principles	  can	  be	  exploited	  in	  the	  rational	  design	  of	  an	  improved	  
TEVG,	  including	  via	  the	  use	  of	  associated	  computational	  models.	  	  	  
	   Although	  TEVGs	  designed	  for	  the	  venous	  circulation	  achieved	  success	  in	  a	  
pilot	  clinical	  study,	  arterial	  TEVGs	  lag	  behind	  primarily	  due	  to	  the	  difficulties	  of	  
creating	  a	  degradable	  scaffold	  that	  can	  withstand	  pulsatile	  high-­‐pressure	  arterial	  
blood	  flow.	  	  Clinical	  translation	  of	  arterial	  TEVGs	  has	  been	  achieved	  only	  by	  
McAllister	  and	  colleagues	  with	  sheet	  based	  TEVGs	  used	  as	  arteriovenous	  shunts	  for	  
hemodialysis	  in	  patients	  with	  end	  stage	  kidney	  disease.53	  	  While	  initially	  successful,	  
complications	  were	  encountered	  in	  the	  3	  out	  of	  10	  patients	  who	  developed	  graft	  
thrombosis,	  dilation,	  and	  aneurysm	  respectively.54	  	  Moreover,	  the	  cell	  sheet	  
technique	  required	  several	  weeks	  to	  mature	  in	  culture	  prior	  to	  implantation.55	  	  Due	  
to	  these	  limitations	  it	  remains	  unclear	  if	  a	  cell	  sheet	  based	  TEVG	  would	  be	  suitable	  
in	  the	  pediatric	  population	  where	  delayed	  intervention	  can	  result	  in	  increased	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morbidity.	  	  Recent	  work	  by	  the	  same	  group	  using	  allogeneic	  cells	  to	  grow	  a	  TEVG	  
prior	  to	  implantation	  has	  shown	  promise.	  	  	  Through	  this	  method,	  TEVGs	  were	  
created	  from	  allogeneic	  sheets	  of	  fibroblasts	  and	  then	  stored	  for	  several	  months	  
prior	  to	  implant.	  	  In	  this	  way	  the	  pre-­‐made	  TEVGs	  came	  closer	  to	  achieving	  an	  “off-­‐
the-­‐shelf”	  potential.	  	  However,	  the	  clinical	  translation	  of	  this	  technique	  is	  in	  early	  
stages	  and	  complications	  have	  arisen	  in	  2	  of	  the	  3	  patients	  receiving	  grafts.56	  	  In	  
contrast,	  the	  work	  described	  herein	  utilizes	  a	  same	  day	  seeding	  and	  implantation	  
method	  similar	  to	  that	  used	  in	  venous	  TEVGs	  that	  have	  proven	  efficacious	  in	  a	  pilot	  
clinical	  study.25,26	  	  	  
Vascular	  neotissue	  formation	  describes	  the	  process	  by	  which	  a	  
biodegradable	  scaffold	  transforms	  into	  a	  living	  vascular	  conduit,	  whether	  initially	  
seeded	  with	  cells	  or	  not.	  	  As	  the	  scaffold	  degrades,	  neotissue	  forms	  and	  ultimately	  
gives	  rise	  to	  a	  neovessel	  when	  the	  scaffolding	  is	  degraded	  completely.	  	  Despite	  
significant	  advances	  in	  our	  understanding	  of	  mechanobiological	  factors	  affecting	  
vascular	  biology	  in	  health	  and	  disease,	  there	  has	  been	  little	  research	  on	  these	  
processes	  during	  neovessel	  formation.	  	  The	  biomechanical	  properties	  of	  the	  TEVG	  
are	  initially	  determined	  exclusively	  by	  the	  properties	  of	  the	  tubular	  scaffold,	  but	  
over	  time	  the	  cells	  begin	  to	  produce	  an	  extracellular	  matrix	  that	  increasingly	  
contributes	  to	  the	  properties	  of	  the	  graft.	  As	  in	  native	  blood	  vessels,	  this	  
extracellular	  matrix	  is	  composed	  primarily	  of	  collagen,	  elastin,	  and	  
glycosaminoglycans.	  	  As	  the	  scaffold	  degrades,	  it	  is	  thought	  that	  the	  cells	  can	  sense	  
the	  increased	  load	  borne	  by	  the	  deposited	  extracellular	  matrix,	  which	  it	  presumably	  
remodels	  or	  refashions	  in	  an	  attempt	  to	  establish	  the	  aforementioned	  mechanical	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homeostasis.	  	  At	  the	  point	  when	  the	  scaffold	  degrades	  completely,	  the	  extracellular	  
matrix	  is	  necessarily	  the	  primary	  determinant	  of	  the	  biomechanical	  properties	  of	  
the	  graft	  and	  hence	  both	  the	  overall	  structural	  integrity	  and	  its	  adaptive	  potential.	  
Recent	  work	  by	  Naito,	  Lee,	  and	  colleagues	  demonstrated	  that	  developing	  venous	  
TEVGs	  composed	  of	  an	  initially	  stiff	  (poly)glycolic	  acid	  scaffold	  develop	  increased	  
compliance	  that	  approaches	  native	  IVC	  by	  24	  weeks	  after	  implantation.43	  	  This	  work	  
has	  indicated	  a	  complex,	  time-­‐dependent	  process	  in	  which	  collagen	  deposited	  
during	  the	  first	  12	  weeks	  is	  replaced	  or	  remodeled	  into	  more	  compliant	  forms	  in	  the	  
context	  of	  a	  fully	  degraded	  PGA	  scaffold.	  See,	  too,	  the	  associated	  modeling	  study	  by	  
Miller	  and	  colleagues	  that	  captures	  salient	  aspects	  of	  the	  associated	  biomechanics.44	  
The	  present	  study	  was	  designed	  to	  determine	  if	  similar	  mechanobiological	  
processes	  occur	  in	  neovessel	  formation	  within	  the	  arterial	  system	  and	  to	  generate	  
mechanical	  data	  to	  serve	  as	  a	  foundation	  for	  the	  extension	  of	  the	  prior	  
computational	  modeling	  to	  the	  arterial	  system.	  	  We	  found	  that,	  despite	  initial	  
mortality	  associated	  with	  seam	  line	  rupture,	  arterial	  TEVGs	  were	  stable	  after	  6	  
weeks	  with	  no	  aneurysmal	  dilation	  or	  stenosis.	  	  Similar	  to	  the	  work	  of	  Mirensky	  et	  
al.33,	  TEVGs	  developed	  a	  luminal	  endothelial	  cell	  layer	  as	  well	  as	  a	  smooth	  muscle	  
cell	  populated	  “medial”	  layer.	  	  Structurally,	  our	  results	  revealed	  many	  of	  
components	  of	  a	  normal	  extracellular	  matrix,	  including	  elastin	  and	  collagen	  types	  I	  
and	  III.57	  	  MMP-­‐2	  and	  MMP-­‐9	  activity,	  along	  with	  extensive	  infiltration	  by	  
macrophages,	  suggested	  an	  ongoing	  inflammatory	  mediated	  process	  of	  remodeling.	  	  
This	  chronic	  inflammation	  likely	  resulted	  from	  the	  persistence	  of	  the	  PLA,	  which	  
further	  contributed	  to	  the	  continued	  low	  compliance	  in	  both	  the	  circumferential	  and	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axial	  directions.	  	  That	  is,	  the	  elastin	  found	  histologically	  played	  no	  mechanical	  role	  
in	  overall	  TEVG	  performance	  while	  the	  collagen	  contributed	  only	  moderately	  to	  the	  
stiffness.	  	  Hence,	  although	  the	  graft	  satisfied	  minimal	  mechanical	  requirements,	  such	  
as	  sufficient	  suture	  retention	  and	  burst	  pressure,	  and	  clinical	  requirements,	  such	  as	  
lack	  of	  stenosis	  or	  aneurysmal	  expansion,	  it	  clearly	  had	  not	  approached	  native	  
structure	  or	  function	  by	  7	  months.	  
Not	  only	  are	  the	  properties	  of	  the	  TEVG	  important	  for	  its	  integrity	  and	  
adaptivity,	  they	  are	  also	  important	  determinants	  of	  mechanobiological	  adjustments	  
by	  the	  adjacent	  host	  vessels.	  Toward	  this	  end,	  we	  observed	  a	  persistent	  
compensation	  by	  the	  native	  IAA	  in	  response	  to	  the	  high	  stiffness	  of	  the	  TEVG.	  	  At	  the	  
composite	  vessel’s	  in	  vivo	  axial	  stretch,	  a	  near	  constant	  force	  could	  be	  achieved	  
through	  a	  range	  of	  pressures,	  similar	  to	  that	  of	  native	  arteries	  in	  the	  preferred	  
homeostatic	  state.58	  	  Yet,	  the	  axial	  force	  in	  the	  composite	  vessels	  was	  lower	  by	  ~4	  
mN	  compared	  with	  the	  axial	  force	  in	  non-­‐implanted	  IAA	  in	  C57BL/129sv	  mice47;	  
likewise,	  there	  was	  a	  decreased	  compliance	  in	  the	  proximal	  IAA	  relative	  to	  normal	  
(Fig.	  12).	  	  Although	  differences	  in	  mouse	  backgrounds	  (pure	  versus	  mixed	  C57BL/6)	  
and	  testing	  procedures	  (e.g.,	  pressurization	  up	  to	  100	  mmHg	  rather	  than	  140	  
mmHg)	  may	  have	  contributed	  to	  the	  observed	  differences,	  both	  differences	  seen	  in	  
Fig.	  12	  likely	  resulted	  from	  the	  adjacent	  host	  aorta	  adapting	  to	  the	  stiff	  
interpositional	  TEVG.	  Optimal	  design	  of	  TEVGs	  should	  clearly	  seek	  to	  minimize	  













Figure	  12:	  	  Comparison	  of	  IAA	  in	  mice	  with	  and	  without	  
TEVG	  implant.	  	  Pressure	  diameter	  curve	  	  (a)	  and	  pressure-­‐
force	  curve	  (b)	  between	  non-­‐implanted	  (WT)	  mice	  and	  
proximal	  IAA	  (PA)	  in	  mice	  with	  TEVG	  implant	  at	  7	  months.	  	  	  
Non-­‐implanted	  data	  adapted	  with	  permission	  from	  Ferruzzi	  
et	  al.	  	  	  Data in graphs are expressed as mean ± SEM.	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This	  study	  is	  the	  first	  to	  examine	  the	  long-­‐term	  structure	  and	  properties	  
associated	  with	  neovessel	  formation	  in	  the	  arterial	  system.	  The	  data	  confirm	  the	  
importance	  of	  overlapping	  inflammatory	  and	  mechanobiologically	  mediated	  matrix	  
production	  seen	  before	  in	  venous	  TEVGs	  (cf.	  44).	  This	  work	  also	  highlights	  the	  
importance	  of	  mechanical	  evaluations	  of	  evolving	  TEVGs	  that	  delineate	  effects	  of	  
different	  matrix	  components	  as	  complements	  to	  traditional	  histological	  and	  
biochemical	  analysis,	  for	  the	  mere	  presence	  of	  significant	  matrix	  need	  not	  imply	  
significant	  load	  carrying	  capability.	  	  It	  is	  hoped	  that	  such	  data	  can	  inform	  
computational	  models	  that	  can	  predict	  preferred	  time	  courses	  of	  polymer	  
degradation	  and	  matrix	  incorporation	  within	  the	  evolving	  graft.	  Such	  models	  have	  
the	  potential	  to	  decrease	  both	  the	  time	  and	  expense	  associated	  with	  purely	  trial	  and	  
error	  experimental	  approaches	  to	  improving	  tissue	  engineered	  vessels	  and	  thereby	  
to	  open	  the	  door	  for	  next	  generation	  rationally	  designed	  TEVGs.	  
While	  we	  did	  not	  see	  evolution	  of	  the	  mechanical	  properties	  of	  the	  PLA	  
TEVGs	  examined	  in	  this	  study,	  all	  developed	  techniques	  can	  be	  readily	  applied	  to	  
TEVGs	  composed	  of	  other	  scaffold	  biomaterials.	  	  The	  next	  steps	  in	  vascular	  tissue	  
engineering	  for	  the	  arterial	  circulation	  will	  necessitate	  a	  reexamination	  of	  these	  
biomaterials.	  	  A	  balance	  is	  needed	  between	  initial	  strength	  to	  prevent	  aneurysm	  and	  
gradual	  degradation	  to	  encourage	  development	  of	  mechanically	  active	  extracellular	  
matrix	  products.	  	  The	  results	  of	  this	  work	  show	  collagen	  production	  reaches	  a	  
steady	  point	  by	  3	  months,	  thus	  suggesting	  that	  complete	  scaffold	  degradation	  by	  
this	  time	  may	  be	  tolerated.	  	  New	  methods	  of	  scaffold	  production	  such	  as	  
electrospinning	  offer	  one	  possibility.	  	  Electrospun	  scaffolds	  are	  generated	  using	  a	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polymer	  solution	  that	  is	  ejected	  across	  a	  charged	  field	  that	  is	  grounded	  upon	  a	  
spinning	  mandrel.	  	  In	  this	  way,	  a	  scaffold	  can	  be	  “spun”	  that	  contains	  no	  seam	  line	  
and	  its	  initial	  properties	  such	  as	  fiber	  orientation	  and	  graft	  porosity	  can	  be	  
manipulated	  by	  changing	  the	  rate	  of	  polymer	  ejection	  and	  scaffold	  rotation.59	  	  
Recent	  in	  vivo	  results	  using	  this	  technique	  have	  been	  promising	  and	  have	  
demonstrated	  biocompatibility	  of	  a	  number	  of	  polymer	  solutions.60-­‐65	  	  Moreover,	  the	  
lack	  of	  a	  seam	  line	  in	  electrospun	  scaffolds	  eliminates	  an	  inherent	  weakness	  in	  
scaffolds	  composed	  of	  woven	  sheets	  that	  accounted	  for	  the	  vast	  majority	  of	  our	  
mortality.	  	  	  
In	  summary,	  we	  report	  the	  first	  in	  depth	  examination	  of	  arterial	  TEVG	  
mechanical	  properties	  and	  corresponding	  histologic	  properties	  at	  late	  term	  time	  
points.	  	  These	  PLA-­‐PCLA	  grafts	  performed	  well	  with	  the	  notable	  exception	  of	  seam	  
line	  rupture	  in	  the	  early	  weeks	  after	  implantation.	  	  Although	  stable,	  these	  grafts	  did	  
not	  demonstrate	  appreciable	  evolution	  of	  mechanical	  properties	  between	  3	  and	  7	  
months.	  	  Using	  new	  techniques	  for	  evaluating	  individual	  contributions	  of	  collagen	  
and	  elastin,	  with	  correlations	  with	  histologic	  and	  immunohistochemical	  results,	  we	  
found	  that	  there	  was	  evidence	  of	  cellular	  and	  ECM	  development	  between	  these	  time	  
points	  but	  no	  change	  in	  the	  ample	  residual	  PLA	  scaffolds.	  	  It	  is	  likely	  that	  this	  
residual	  PLA	  played	  a	  key	  role	  in	  determining	  overall	  graft	  mechanics,	  and	  its	  long-­‐
term	  presence	  within	  the	  graft	  may	  impede	  graft	  development.	  	  Thus	  a	  reevaluation	  
of	  initial	  scaffold	  material	  will	  be	  a	  crucial	  step	  in	  the	  development	  of	  arterial	  TEVGs.	  	  
Fortunately	  with	  the	  advent	  of	  the	  described	  techniques	  that	  allow	  for	  computation	  
of	  overall	  graft	  mechanics,	  it	  may	  be	  possible	  to	  evaluate	  these	  new	  materials	  in	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silico,	  prior	  to	  in	  vitro	  and	  in	  vivo	  experimentation.	  Such	  computations	  could	  greatly	  
accelerate	  next	  generation	  TEVG	  development	  and	  decrease	  the	  overall	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